Stem Cells International · 2016 · 72 citations · 37 references
Life SciencesCell BiologyObstetricsInflammationRegenerative MedicineStem Cell BiologyAdipocyte DifferentiationMesenchymal DifferentiationMesenchymal Stem Cell TherapyMesenchymal Stromal Cell TherapyMesodermal DifferentiationPlacental BiologyBone Marrow Mesenchymal Stem CellsBone Marrow-derived Mesenchymal Stromal CellsDecidua BasalisMesenchymal Stromal Cell CharacterizationMesenchymal Stromal Cell DifferentiationMesenchymal Stromal Cell PhenotypingPlacenta-derived Mesenchymal Stromal CellsPlacental Cells
Mesenchymal stem cell (MSC) therapies for the treatment of diseases associated with inflammation and oxidative stress employ primarily bone marrow MSCs (BMMSCs) and other MSC types such as MSC from the chorionic villi of human term placentae (pMSCs). These MSCs are not derived from microenvironments associated with inflammation and oxidative stress, unlike MSCs from the decidua basalis of the human term placenta (DBMSCs). DBMSCs were isolated and then extensively characterized. Differentiation of DBMSCs into three mesenchymal lineages (adipocytes, osteocytes, and chondrocytes) was performed. Real-time polymerase chain reaction (PCR) and flow cytometry techniques were also used to characterize the gene and protein expression profiles of DBMSCs, respectively. In addition, sandwich enzyme-linked immunosorbent assay (ELISA) was performed to detect proteins secreted by DBMSCs. Finally, the migration and proliferation abilities of DBMSCs were also determined. DBMSCs were positive for MSC markers and HLA-ABC. DBMSCs were negative for hematopoietic and endothelial markers, costimulatory molecules, and HLA-DR. Functionally, DBMSCs differentiated into three mesenchymal lineages, proliferated, and migrated in response to a number of stimuli. Most importantly, these cells express and secrete a distinct combination of cytokines, growth factors, and immune molecules that reflect their unique microenvironment. Therefore, DBMSCs could be attractive, alternative candidates for MSC-based therapies that treat diseases associated with inflammation and oxidative stress.
37
Guangwen Ren, Xin Zhao, Liying Zhang et al. · The Journal of Immunology · 2010 · 651 citations · Full text